By Tim Wright, Editor, Contract Pharma03.02.22
Oral solids are cost-effective, easy to manufacture and patient-friendly, making them the most common dosage form in the pharmaceutical industry. In addition, advances in drug delivery technology, such as targeted drug delivery and sustained release dosage forms, are enabling oral solids to achieve even greater levels of bioavailability while reducing the frequency of drug administration. Other benefits exist in terms of relatively uncomplicated packaging needs and storage and distribution requirements due to chemical and physical stability.
As the most preferred drug delivery form, oral solids are used across a wide spectrum of the pharmaceutical landscape. In fact, the small molecule outsourcing market is expected to reach $69.4 billion by 2024, with the demand being driven by complex molecules, according to Visiongain’s report, “Pharmaceutical Contract Manufacturing Market 2019-2029.”
Over the past several months, contract development and manufacturing organizations (CDMOs) have continued to invest in and expand their oral solid dosage (OSD) development and manufacturing capabilities to meet the growing demands of the market. Some
As the most preferred drug delivery form, oral solids are used across a wide spectrum of the pharmaceutical landscape. In fact, the small molecule outsourcing market is expected to reach $69.4 billion by 2024, with the demand being driven by complex molecules, according to Visiongain’s report, “Pharmaceutical Contract Manufacturing Market 2019-2029.”
Over the past several months, contract development and manufacturing organizations (CDMOs) have continued to invest in and expand their oral solid dosage (OSD) development and manufacturing capabilities to meet the growing demands of the market. Some
Continue reading this story and get 24/7 access to Nutraceuticals World for FREE
FREE SUBSCRIPTION
